Plain-English translation of NCT06916806 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This is an early-stage clinical trial testing a new medication called for three autoimmune diseases: systemic lupus erythematosus, idiopathic inflammatory myopathies, and rheumatoid arthritis. Researchers want to understand how the medication works in your body, how safe it is, and how well you tolerate it. The study has two parts: the first tests single doses, and the second tests a two-dose approach given one week apart.
Current treatments don't work well enough or cause intolerable side effects for many patients with these autoimmune diseases. This trial is exploring whether this medication could offer a better treatment option for people who haven't responded well to existing therapies.
You likely qualify if…
You likely don't qualify if…
If you're in Part 1, you'll visit the clinic for screening (up to 6 weeks), receive one injection under the skin, and then return for follow-up visits over the next 6 months. If you're in Part 2, you'll receive two injections under the skin one week apart, followed by similar follow-up visits. Throughout the study, you'll have blood tests and physical exams to monitor how the medication affects your body and how you feel.
AI-generated summary from trial data · Aug 2, 2026 · Not medical advice
United States